Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
Edesa Biotech announced progress in preparations for its Phase 2 clinical trial of EB06, an anti-CXCL10 monoclonal antibody targeting moderate-to-severe nonsegmental vitiligo. The company has selected JSS Medical Research as its clinical research organization and expects to begin patient enrollment and site activation by mid-2026, starting in Canad…